author-photo

Bonnie Chandler Abbruzzese

48

Papers

157

Citations

Citation Trend

Filter By

Papers (33) Sort By

Journal Conference Others

Intravenous 99mTc-tilmanocept in Planar and Fused SPECT/CT Imaging of Activated Macrophage Infiltration in Subjects with Metastatic Liver Colorectal Adenocarcinoma (ML-CRC).

2018 The Journal of Nuclear Medicine
Show All
- Source
- Cite
- Save
Citations (1)
AB0248 Evaluation of subcutaneously (SC) injected tc 99m tilmanocept localization in active rheumatoid arthritis (RA) subjects by planar and spect/ct

2018 Annals of the Rheumatic Diseases
Show All
- Source
- Cite
- Save
Citations (1)
Use of 99mTc-tilmanocept and related molecular constructs for identifying and diagnosing malignant tumors and for monitoring therapeutic anti-tumor interventions

2018
Show All
- Source
- Cite
- Save
Citations (0)
Application of a Novel CD206+ Macrophage-Specific Arterial Imaging Strategy in HIV-Infected Individuals

2017 The Journal of Infectious Diseases
Show All
- Source
- Cite
- Save
Citations (24)
Corrigendum to the inextricable axis of targeted diagnostic imaging and therapy: An immunological natural history approach [Nucl Med Biol 43 (2016) 215–225]

2016 Nuclear Medicine and Biology
Show All
- Source
- Cite
- Save
Citations (0)
The inextricable axis of targeted diagnostic imaging and therapy: An immunological natural history approach ☆

2016 Nuclear Medicine and Biology
Show All
- Source
- Cite
- Save
Citations (12)
101. 99mTc-Tilmanocept (TcTm) provides stably localised detection of lymph nodes (LN) in melanoma across all anatomic locations regardless of body mass index (BMI), or day of surgery

2014 Ejso
Show All
- Source
- Cite
- Save
Citations (0)
A 3-year follow-up study of breast cancer (BC) or melanoma (ME) patients (Pts) who underwent sentinel node biopsy (SLNB) indicates a <2% false negative rate performance with CD206 receptor-targeted 99mTc-tilmanocept (TcTm) as the sole intraoperative lymphatic mapping agent

2014
Show All
- Source
- Cite
- Save
Citations (0)
The high sensitivity (SEN) of 99mTc-Tilmanocept (TcTm) is unaffected by injection route and interval from injection to surgery across solid tumor types [breast cancer (BC), melanoma (ME) & head/neck squamous cell carcinoma (HNSCC)]

2014 The Journal of Nuclear Medicine
Show All
- Source
- Cite
- Save
Citations (1)
104. The false negative rate (FNR) for 99mTc-tilmanocept is crucially low across breast cancer (BC), melanoma (ME), and head/neck squamous cell carcinoma (HNSCC), portending good patient outcome

2014 Ejso
Show All
- Source
- Cite
- Save
Citations (1)